Study Status: Recruiting
Recruit Status: Recruiting
Study Type: Interventional
Official Title: Phase II Study of the Dose Adjusted EPOCH Regimen in Combination With Ofatumumab/Rituximab as Therapy for Patients With Newly Diagnosed or Relapsed/Refractory Burkitt Leukemia
Brief Summary: The goal of this clinical research study is to learn if adding ofatumumab/rituximab to the standard combination of DA-EPOCH (dose-adjusted etoposide, prednisone, vincristine, and cyclophosphamide) can help control the disease in patients with newly diagnosed or relapsed/refractory Burkitt leukemia or relapsed/refractory ALL. The safety of this drug combination will also be studied.